https://www.selleckchem.com/pr....oducts/nazartinib-eg
2%, p 0.00001). Analogously, BZD use was over-represented in the DEL+ group with respect to the DEL- one (73.3% vs. 22.8%, p 0.00001). DEL prevalence as detected by GP during programmed home visits is surprisingly high, and related to motor impairment, comorbidities (among which dementia), and BZD use. DEL prompt recognition should be one of the goals of GP-programmed home visits, since this treatable and preventable condition is associated to an elevated burden of frailty and risk of death. DEL prevalence as